Ocrelizumab
Discovery
Development
Clinical
Filed
Commercialized
Therapeutic area
Therapeutic area
Neuroimmunology, Multiple Sclerosis
Reference product
Reference product
Ocrevus® (Roche)
Commercial partners
Commercial partners
Teva, MS Pharma, Tuteur
Status
Status
Clinical
About this program
Ocrelizumab is a biosimilar developed to match Ocrevus®, a reference biologic used in the treatment of Multiple Sclerosis.
Commercialization partners
Teva
US
EU
BRA
CAN
ANZ
IL
TK
MS-Pharma
Middle East
Tuteur
LATAM ex-BRA
Let's build together.
If you want to explore what a partnership with us could look like, we're ready to talk.